Jazz Pharmaceuticals To Report 2012 Fourth Quarter And Full Year Financial Results On February 26, 2013
DUBLIN, Feb. 11, 2013 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will host a conference call and live webcast on Tuesday, February 26, 2013 at 4:30 p.m. EST/9:30 p.m. GMT. During the call, company management will provide a business and financial update and review its 2012 fourth quarter and full year financial results.
A live webcast of the presentation may be accessed from the Investors & Media section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. Please connect to the website prior to the start of the conference call to ensure adequate time for any software downloads that may be necessary to listen to the webcast.
Investors may participate in the conference call by dialing +1-800-920-8624 in the U.S., or +1-617-597-5430 outside the U.S., and entering passcode 75109778.
A replay of the conference call will be available through March 5, 2013 by dialing +1-888-286-8010 in the U.S., or +1-617-801-6888 outside the U.S., and entering passcode 53780559.
An archived version of the webcast will be available for at least one week on the Investors section of the company's website at www.jazzpharmaceuticals.com.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing innovative products that address unmet medical needs. The company has a diverse portfolio of products in the areas of narcolepsy, oncology, pain and psychiatry. The company's U.S. marketed products in these areas include: Xyrem® (sodium oxybate) oral solution, Erwinaze® (asparaginase Erwinia chrysanthemi), Prialt® (ziconotide) intrathecal infusion, Luvox CR® (fluvoxamine maleate), FazaClo® (clozapine, USP) HD and FazaClo LD. Outside of the U.S., Jazz Pharmaceuticals also has a number of products marketed by its international division, EUSA Pharma. For further information, see www.jazzpharmaceuticals.com.
SOURCE Jazz Pharmaceuticals plc
More by this Source
Jazz Pharmaceuticals to Report 2016 First Quarter Financial Results on May 10, 2016
26 Apr, 2016, 21:05 BST
Jazz Pharmaceuticals Announces Webcast for Defitelio® (defibrotide sodium) Investor Update
30 Mar, 2016, 19:57 BST
Jazz Pharmaceuticals Announces FDA Approval of Defitelio® (defibrotide sodium) for the Treatment of Hepatic Veno-Occlusive Disease (VOD) with Renal or Pulmonary Dysfunction Following Hematopoietic Stem-Cell Transplantation (HSCT)
30 Mar, 2016, 19:50 BST
Get content for your website
Enhance your website's or blog's content with PR Newswire's customised real-time news feeds.
Contact PR Newswire
Send us an email at MarketingUK@prnewswire.co.uk or call us at +44 (0)20 7454 5382
Become a PR Newswire client
Request more information about PR Newswire products & services or call us at +44 (0)20 7454 5382